Table 1: Characteristics of study participants.

Coronary artery stenosis value
(−)(+)
= 19 = 17

Age (years)57 ± 1562 ± 70.094
Male/female9/1012/50.192
BMI (kg/m2) 26.4 ± 5.727.2 ± 4.80.642
Duration of diabetes (years)3.0 (1.0–11.0)6.0 (12.0–20.5)0.007
Hypertension, (%)12 (63)14 (82)0.274
Systolic blood pressure (mmHg)123 ± 19138 ± 150.015
Diastolic blood pressure (mmHg)73 ± 1377 ± 100.448
Smoking, (%)10 (53)8 (47)1.000
Retinopathy, (%)3 (16)12 (71)0.002
Nephropathy, (%)6 (32)11 (65)0.057
Neuropathy, (%)12 (63)14 (83)0.274
HbA1c (%)10.1 ± 1.89.5 ± 1.30.313
Fasting plasma glucose (mmol/L)8.1 ± 2.47.9 ± 2.00.856
Total cholesterol (mmol/L)5.02 ± 0.964.58 ± 0.970.183
LDL cholesterol (mmol/L)3.13 ± 0.822.76 ± 0.790.185
HDL cholesterol (mmol/L)1.20 ± 0.380.98 ± 0.150.031
MDA-LDL (U/L)70 ± 4093 ± 570.161
MDA-LDL/LDL-C (U/mmol)23.3 ± 12.332.9 ± 11.30.020
MDA-LDL/HDL-C (U/mmol)63.8 ± 45.3100.3 ± 74.40.080
(MDA-LDL/LDL-C)/HDL-C (U·L/mmol2)21.3 ± 13.834.9 ± 15.20.008
Triglycerides (mmol/L)1.50 ± 0.601.82 ± 0.710.148
Medications, (%)
 Insulin treatment8 (42)3 (18)0.156
 Sulfonylurea6 (32)6 (35)1.000
 Glinides2 (11)2 (12)1.000
 Metformin7 (37)9 (53)0.503
 Thiazolidinedione0 (0)2 (12)0.216
-Glucosidase inhibitor0 (0)3 (18)0.095
 Incretin-related therapies5 (26)8 (47)0.299
 Statin8 (42)7 (41)1.000

Data are mean ± SD or median (interquartile range). BMI: body mass index; hypertension: systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg or treatment; MDA-LDL: malondialdehyde-modified LDL; MDA-LDL-C/LDL-C: MDA-LDL-to-LDL cholesterol ratio; MDA-LDL-C/HDL-C: MDA-LDL-to-HDL cholesterol ratio; (MDA-LDL/LDL-C)/HDL-C: (MDA-LDL/LDL-C) to HDL cholesterol ratio.